U.S. markets open in 6 hours 43 minutes
  • S&P Futures

    4,391.50
    -3.00 (-0.07%)
     
  • Dow Futures

    34,899.00
    -54.00 (-0.15%)
     
  • Nasdaq Futures

    14,929.00
    -18.75 (-0.13%)
     
  • Russell 2000 Futures

    2,190.40
    +3.70 (+0.17%)
     
  • Crude Oil

    72.11
    +0.46 (+0.64%)
     
  • Gold

    1,804.50
    +4.70 (+0.26%)
     
  • Silver

    24.84
    +0.20 (+0.80%)
     
  • EUR/USD

    1.1816
    -0.0010 (-0.08%)
     
  • 10-Yr Bond

    1.2340
    0.0000 (0.00%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3872
    -0.0007 (-0.05%)
     
  • USD/JPY

    109.8870
    +0.1200 (+0.11%)
     
  • BTC-USD

    39,395.88
    +2,150.38 (+5.77%)
     
  • CMC Crypto 200

    920.63
    +44.40 (+5.07%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of RMO, PTON and FREQ

·4 min read

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Romeo Power, Inc. (NYSE:RMO)
Class Period: October 5, 2020 - March 30, 2021
Lead Plaintiff Deadline: June 15, 2021

The complaint alleges that during the class period Romeo Power, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.

Learn about your recoverable losses in RMO: http://www.kleinstocklaw.com/pslra-1/romeo-power-inc-loss-submission-form?id=16803&from=1

Peloton Interactive, Inc. (NASDAQ:PTON)
Class Period: September 11, 2020 - May 5, 2021
Lead Plaintiff Deadline: June 28, 2021

The complaint alleges Peloton Interactive, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, Peloton's Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+, yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission ("CPSC") declared that the Tread+ posed a serious risk to public health and safety and urgently recommended that consumers with small children cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, defendants' statements about Peloton's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in PTON: http://www.kleinstocklaw.com/pslra-1/peloton-interactive-inc-loss-submission-form?id=16803&from=1

Frequency Therapeutics, Inc. (NASDAQ:FREQ)
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021

During the class period, Frequency Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

Learn about your recoverable losses in FREQ: https://www.kleinstocklaw.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?id=16803&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/651433/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-RMO-PTON-and-FREQ